[HTML][HTML] Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines

…, J Gerald, RT Brown, MK Herring… - … England Journal of …, 2021 - Mass Medical Soc
Background Information is limited regarding the effectiveness of the two-dose messenger
RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in …

[HTML][HTML] Animal reservoirs and hosts for emerging alphacoronaviruses and betacoronaviruses

…, AY Liew, KB Martin, MK Herring… - Emerging Infectious …, 2021 - ncbi.nlm.nih.gov
The ongoing global pandemic caused by coronavirus disease has once again demonstrated
the role of the family Coronaviridae in causing human disease outbreaks. Because severe …

[HTML][HTML] Research on the epidemiology of SARS-CoV-2 in essential response personnel (RECOVER): protocol for a multisite longitudinal cohort study

…, AL Phillips, L Grant, MK Herring… - JMIR research …, 2021 - researchprotocols.org
Background Workers critical to emergency response and continuity of essential services
during the COVID-19 pandemic are at a disproportionally high risk of SARS-CoV-2 infection. …

[HTML][HTML] Risk factors for reinfection with SARS-CoV-2 Omicron variant among previously infected frontline workers

…, L Grant, JK Romine, MK Herring… - Emerging infectious …, 2023 - ncbi.nlm.nih.gov
In a cohort of essential workers in the United States previously infected with SARS-CoV-2,
risk factors for reinfection included being unvaccinated, infrequent mask use, time since first …

[HTML][HTML] COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers

…, P Rivers, AL Naleway, K Nguyen, M Herring… - Vaccine, 2022 - Elsevier
Introduction In a multi-center prospective cohort of essential workers, we assessed knowledge,
attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and …

Neutralizing antibody response to pseudotype severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differs between mRNA-1273 and BNT162b2 …

…, SK Yoon, MK Herring… - Clinical infectious …, 2022 - academic.oup.com
Background Data on the development of neutralizing antibodies (nAbs) against SARS-CoV-2
after SARS-CoV-2 infection and after vaccination with mRNA COVID-19 vaccines are …

[HTML][HTML] Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): protocol for a multisite longitudinal cohort study

…, MG Wesley, K Krupp, MK Herring… - JMIR research …, 2022 - researchprotocols.org
Background Assessing the real-world effectiveness of COVID-19 vaccines and understanding
the incidence and severity of SARS-CoV-2 illness in children are essential to inform policy …

Neutralizing antibody response to pseudotype sars-cov-2 differs between mRNA-1273 and Bnt162b2 covid-19 vaccines and by history of sars-cov-2 infection

…, AJ Caban-Martinez, SK Yoon, MK Herring… - medRxiv, 2021 - medrxiv.org
Background Data on the development of neutralizing antibodies against SARS-CoV-2 after
SARS-CoV-2 infection and after vaccination with messenger RNA (mRNA) COVID-19 …

[HTML][HTML] Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses.

MK Herring, JK Romine, MG Wesley… - Clin Infect …, 2023 - pesquisa.bvsalud.org
BACKGROUND: Data on antibody kinetics are limited among individuals previously infected
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of …

Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses

MK Herring, JK Romine, MG Wesley… - Clinical Infectious …, 2023 - academic.oup.com
Background Data on antibody kinetics are limited among individuals previously infected
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of …